Nope, just RUnning some comparables.RU sure?
Nope, just RUnning some comparables.RU sure?
You don't even know your own age nor what a boomer is.I'm 22 boomer
This. Though I disagree about saying there's much more money to be made in other fields. Kirkland foam sells insanely well, and Rogaine must be worth millions. male pattern baldness is a stupidly profitable sectorI talked to the Doctor who did the 6 month human Trial on RU. He said it was likely stopped because of financial reasons. You can make much more Money in other fields of medicine and therefore companies usually don't care about Hair loss.
And If you compare RU to Nilutamide you have to remember that RU metabolizes in the body. Only 1% gets metabolized into Cyanonilutamide. So even when you apply 100mg of RU you should only have 1mg of Cyanonilutamide in your body. It is very unlikely that that would have the same Side effect profile as 150mg Nilutamide oral.
I think Rogaine sells better because it is non-prescription and a lot of people don't want to use prescription drugs for cosmetical Problems.This. Though I disagree about saying there's much more money to be made in other fields. Kirkland foam sells insanely well, and Rogaine must be worth millions. male pattern baldness is a stupidly profitable sector
They claimed that? Source?I think Rogaine sells better because it is non-prescription and a lot of people don't want to use prescription drugs for cosmetical Problems.
The company that did the Research on RU (PSK-3841) labeled it as a non-priority and claimed there would only be a modest Market for the compound. And that is very likely the reason the research did not continue.
They claimed that? Source?
I'm Not Sure about that.Isn't that Morgan stanleys saying "we belive that..." ?
Maybe due to the fact that they couldn't patent ru58841...I'm Not Sure about that.
But the Company Prostrakan tried to outsource the compound, which indicates they didn't put much value in it.
Also I spoke to the Doctor who conducted the human Trial and he said that the Research was likely stopped because of financial reasons.